Technische Universität München Hospital is First in Germany to Treat Cancer Patients with Accuray Radixact® System

SUNNYVALE, Calif., Oct. 9, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Klinikum rechts der Isar der Technischen Universität München (TUM) clinical team has treated the first cancer patients in Germany with the innovative Radixact^® System. This next-generation helical radiation therapy technology replaced an existing, earlier generation TomoTherapy^® System at TUM, reinforcing its value to the hospital as a workhorse radiation therapy device capable of treating a wide range of indications from simple to complex. The TUM patients were treated for breast cancer, head and neck tumors, prostate cancer and spinal tumors.

The TUM hospital is focused on providing patients with personalized care using state-of-the-art technology that can deliver high-precision radiation therapy with minimal side effects. The specialized team of experts in radiation therapy and medical physics, and specially trained medical-technical radiology assistants, work closely with other disciplines within the university hospital, referring physicians, and other institutions, to ensure patients receive the best possible treatment for their specific type of cancer.

"Our radiotherapy team has been using the TomoTherapy platform for more than 10 years and have found it to be an essential component of cancer care at the hospital. When it came time to purchase a new radiation therapy device, our long-term positive experiences made the decision to upgrade to the Radixact System an easy one," said Univ. Prof. Dr. med. Stephanie E. Combs, Chair of the Department of Radiation Oncology at Klinikum rechts der Isar Technische Universität München. "We treat patients with a wide variety of tumor types and are excited about the opportunity to treat even complex cases much more quickly, without sacrificing precision or accuracy. In the future, we look forward to improved image guidance, and motion tracking and compensation, enhancements that we believe will enable us to significantly improve patient care."

State-of-the-art technology is designed to empower clinicians to improve their patients' care

• The system is fully-integrated with the Accuray Precision^® Treatment Planning System and the iDMStm Data Management System, enabling the clinical team to increase the ease and speed with which they create treatment plans and deliver precise radiation treatments
• The Radixact System delivers the same highly conformal and homogeneous dose distribution faster than the previous TomoTherapy platform, with a higher dose rate (1000 MU/minute) and imaging time that is 66 percent faster. A combination of higher dose output and faster image acquisition can shorten treatment times, while improving the patient experience
• A fully-integrated, automated adaptive solution, PreciseARTtm Adaptive Radiation Therapy Software, makes adaptive radiotherapy simple and practical. The software enables physicians to easily decide when adaptation of radiation delivery during the course of treatment would be beneficial due to changes in tumor size and patient anatomy
• The CTruetm IR (Iterative Reconstruction) image guidance software improves soft-tissue contrast and reduces noise, enhancing image quality, while maintaining the same low imaging dose and fast reconstruction time as earlier versions of the software. Patient workflows are also more efficient, facilitating the delivery of precise treatments more quickly, for more patients

"We are proud to partner with Professor Combs and her team as they expand access to the Radixact System to German patients," said Lionel Hadjadjeba, M.D., Senior Vice President, and Chief Commercial Officer at Accuray. "Our hope is that our advanced and differentiated approach to treating cancer will provide a new option for patients requiring radiation treatments."

Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.

Safe Harbor Statement 
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, and patient experiences and outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, the company's ability to develop new products or enhance existing products to meet customers' needs, the company's ability to maintain or increase its gross margins on product sales and services, the company's ability to meet the covenants under its credit facilities, the company's ability to convert backlog to revenue, risks and uncertainties related to the China Class A license announcement and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 24, 2018 and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contacts
Beth Kaplan                                                                 
Accuray 
+1 (408) 789-4426
[email protected]

Jayme Maniatis
MSLGROUP
+1 (781) 684-6662
[email protected]

SOURCE Accuray Incorporated